Journal

GLP-1s in Adolescents: What the Evidence Supports and What It Does Not

Approval has extended to adolescents. The evidence base is real but considerably thinner than in adults.

Where the evidence stands

Systematic reviews and meta-analyses of randomised controlled trials in adolescents with obesity or overweight without diabetes have found meaningful weight reduction with GLP-1 receptor agonists, semaglutide in particular. That is a real evidence base, and it supported approval in this age group.

It is also considerably smaller than the adult evidence base. SURMOUNT-1 randomised 2,539 adults. Adolescent trials are smaller, fewer, and shorter. Long-term follow-up into adulthood — which is the timeframe that matters for a drug started at 14 — does not exist yet.

What is genuinely different about treating adolescents

Growth and development. Adolescence involves bone accrual, hormonal change and body composition shifts that adult trials do not model. Peak bone mass is largely established during these years.

Duration. If obesity is chronic and treatment holds its result only while present, a 16-year-old starting treatment is contemplating decades. No trial addresses that horizon.

Nutrition. Appetite suppression in a growing person raises questions about adequacy of intake that do not arise the same way in adults.

The psychological dimension. Weight, body image and adolescence interact in ways that require genuine clinical care rather than a questionnaire, and a treatment that reduces appetite requires monitoring for how it is being used.

What this site will not do

We do not compare providers for adolescent treatment, and we do not publish pricing comparisons aimed at it. Not because prices differ, but because the decision should not be made on price and a comparison table implies it can be.

Adolescent obesity treatment belongs with a paediatric specialist who can assess growth, development, nutrition, psychological wellbeing and family context together. That is a different service from a telehealth intake, whatever the intake form asks.

Questions for a paediatric specialist

1. What have we established about the cause of weight gain in this specific case?
2. What has been tried, for how long, with what support?
3. What monitoring — growth, bone, nutrition, mood — happens during treatment?
4. What is the plan if treatment continues into adulthood, and what if it stops?
5. Who is in the team besides the prescriber?

On compounded products specifically

Everything this site says about compounded preparations applies with more force here. They are not FDA-approved, they have not been through trials in any population, and no adolescent trial has studied one. If treatment is indicated for an adolescent, that is an argument for an approved product prescribed by a specialist, not for the cheapest route.

What the meta-analyses actually measured

Systematic reviews searched randomised controlled trials of GLP-1 receptor agonists in adolescents with obesity or overweight without diabetes. That exclusion matters: it isolates the weight-management question from glycaemic management, and it also narrows the evidence to a smaller set of trials.

The finding is meaningful weight reduction against comparator. What the reviews consistently note is the limited number of trials, their size relative to adult programmes, and the absence of long follow-up.

The horizon problem

SURMOUNT-4 found that adults withdrawn from tirzepatide regained 14% of body weight over the following year while those continuing lost a further 5.5%. If that pattern holds in adolescents, a 15-year-old starting treatment is contemplating continuous therapy across their entire adult life.

No trial addresses that. The longest published follow-up in this field is three years, in adults. Nobody knows what four decades of GLP-1 exposure beginning in adolescence does, because nobody has observed it.

That is not an argument against treatment — untreated adolescent obesity carries its own well-documented trajectory. It is an argument for the decision sitting with a specialist who can weigh both unknowns.

What a specialist assessment covers that an intake form does not

• Growth velocity and pubertal stage, and how treatment interacts with both.
• Bone accrual, which largely completes during these years.
• Nutritional adequacy under appetite suppression in a growing body.
• Screening for disordered eating, where a medication that reduces appetite carries specific risk.
• Family context, which determines whether any plan is sustainable.
• Psychological wellbeing, assessed rather than asked about in a checkbox.

Why we publish no provider comparison for this

Because a comparison table implies the decision turns on price and convenience. For adolescents it turns on whether the assessing clinician can do the work above. That is not a field in a pricing dataset.

The disordered eating question

Adolescence carries the highest incidence of eating disorder onset, and a medication whose primary effect is appetite suppression sits directly on that risk. Screening before starting, and monitoring during treatment, is not an optional extra in this age group.

It is also something a questionnaire cannot do. It requires a clinician who can ask follow-up questions, notice what is not being said, and involve family appropriately.

Why "the adults are fine" is not sufficient reassurance

Adult safety data is reassuring within its population. It says nothing about a body still accruing bone, still growing, and still establishing lifelong patterns of eating. Extrapolating adult safety to adolescents is the same category of error as extrapolating injectable trial results to an orally disintegrating tablet.

Questions readers actually ask